Neurodegenerative models in Drosophila: Polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis

Neurobiology of Disease

Volumn 40, Issue 1, 2010, Pages 29-39

  Ambegaokar, Surendra S ^a   Roy, Bidisha ^a   Jackson, George R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

DJ 1; Drosophila; LRRK2; Neurodegeneration; Parkin; PINK1; Polyglutamine; SOD; Synuclein; TDP 43; VAPB

Indexed keywords

ALPHA SYNUCLEIN; ATAXIN 3; DJ 1 PROTEIN; DYNAMIN I; LEUCINE RICH REPEAT KINASE 2; MEMBRANE PROTEIN; PARKIN; POLYGLUTAMINE; PROTEIN PINK1; RIBONUCLEOPROTEIN; SUPEROXIDE DISMUTASE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DROSOPHILA MELANOGASTER; FRONTOTEMPORAL DEMENTIA; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE MAPPING; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY; IMMUNOREACTIVITY; LETHALITY; MACHADO JOSEPH DISEASE; NIGRONEOSTRIATAL SYSTEM; NITROSYLATION; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; POLYGLUTAMINE DISORDER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SPINOCEREBELLAR DEGENERATION; TRANSGENE; UBIQUITINATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; HUMANS; HUNTINGTON DISEASE; MODELS, GENETIC; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PEPTIDES;

EID: 77955847105     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.05.026     Document Type: Review

References (164)

1. Agrawal N., et al. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl Acad. Sci. USA 2005, 102:3777-3781.
2. Al-Ramahi I., et al. CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J. Biol. Chem. 2006, 281:26714-26724.
3. Al-Ramahi I., et al. dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. PLoS Genet. 2007, 3:e234.
4. Auluck P.K., Bonini N.M. Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 2002, 8:1185-1186.
5. Auluck P.K., et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, 295:865-868.
6. Ayala Y.M., et al. Human, Drosophila, and C. elegans TDP43: nucleic acid binding properties and splicing regulatory function. J. Mol. Biol. 2005, 348:575-588.
7. Bae B.I., et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 2005, 47:29-41.
8. Bellen H.J., et al. The BDGP gene disruption project: single transposon insertions associated with 40% of Drosophila genes. Genetics 2004, 167:761-781.
9. Berman S.B., et al. Bcl-x L increases mitochondrial fission, fusion, and biomass in neurons. J. Cell Biol. 2009, 184:707-719.
10. Bilen J., Bonini N.M. Genome-wide screen for modifiers of ataxin-3 neurodegeneration in Drosophila. PLoS Genet. 2007, 3:1950-1964.
11. Bilen J., et al. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol. Cell 2006, 24:157-163.
12. Bonifati V., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299:256-259.
13. Bossy-Wetzel E., et al. Mitochondrial fission in apoptosis, neurodegeneration and aging. Curr. Opin. Cell Biol. 2003, 15:706-716.
14. Branco J., et al. Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases. Hum. Mol. Genet. 2008, 17:376-390.
15. Brand A.H., Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 1993, 118:401-415.
16. Cha G.H., et al. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc. Natl Acad. Sci. USA 2005, 102:10345-10350.
17. Chai A., et al. hVAPB, the causative gene of a heterogeneous group of motor neuron diseases in humans, is functionally interchangeable with its Drosophila homologue DVAP-33A at the neuromuscular junction. Hum. Mol. Genet. 2007.
18. Chan D.C. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2006, 125:1241-1252.
19. Chen L., Feany M.B. alpha-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 2005, 8:657-663.
20. Chen H.K., et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 2003, 113:457-468.
21. Chen L., et al. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J. Clin. Invest. 2009, 119:3257-3265.
22. Clark I.E., et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-1166.
23. Cookson M.R. The biochemistry of Parkinson's disease. Annu. Rev. Biochem. 2005, 74:29-52.
24. Dagda R.K., et al. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J. Biol. Chem. 2009, 284:13843-13855.
25. Dickey C.A., et al. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species. J. Neurosci. 2006, 26:6985-6996.
26. Dufty B.M., et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am. J. Pathol. 2007, 170:1725-1738.
27. Ehrnhoefer D.E., et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. 2006, 15:2743-2751.
28. Exner N., et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. 2007, 27:12413-12418.
29. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature 2000, 404:394-398.
30. Feiguin F., et al. Depletion of TDP-43 affects Drosophila motoneurons terminal synapsis and locomotive behavior. FEBS Lett. 2009, 583:1586-1592.
31. Fernandez-Funez P., et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 2000, 408:101-106.
32. Foroud T., et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 2003, 60:796-801.
33. Frank S., et al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev. Cell 2001, 1:515-525.
34. Fujiwara H., et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
35. Gendron T.F., et al. TDP-43: Mechanisms of neurodegeneration. Neuropathol. Appl. Neurobiol. 2010, 36:97-112.
36. Giasson B.I., Lee V.M. Parkin and the molecular pathways of Parkinson's disease. Neuron 2001, 31:885-888.
37. Giasson B.I., Lee V.M. Are ubiquitination pathways central to Parkinson's disease?. Cell 2003, 114:1-8.
38. Giasson B.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
39. Gilks W.P., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
40. Gitcho M.A., et al. TDP-43 A315T mutation in familial motor neuron disease. Ann. Neurol. 2008, 63:535-538.
41. Greene J.C., et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl Acad. Sci. USA 2003.
42. Greggio E., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 2006, 23:329-341.
43. Gunawardena S., et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003, 40:25-40.
44. Hanson K.A., et al. Ubiquilin modifies toxicity of the 43 kilodalton TAR-DNA binding protein (TDP-43) in a Drosophila model of amyotrophic lateral sclerosis (ALS). J. Biol. Chem. 2010.
45. Hattori N., Mizuno Y. Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 2004, 364:722-724.
46. Haywood A.F., Staveley B.E. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci. 2004, 5:14.
47. Hedrich K., et al. Distribution, type, and origin of Parkin mutations: review and case studies. Mov. Disord. 2004, 19:1146-1157.
48. Hernandez D., et al. The dardarin G 2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci. Lett. 2005, 389:137-139.
49. Higashiyama H., et al. Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration. Cell Death Differ. 2002, 9:264-273.
50. Hoppins S., et al. The machines that divide and fuse mitochondria. Annu. Rev. Biochem. 2007, 76:751-780.
51. Ibanez P., et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
52. Imai Y., et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell 2001, 105:891-902.
53. Imai Y., et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
54. Jackson G.R., et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998, 21:633-642.
55. Jackson G.R., et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002, 34:509-519.
56. Jiang H., et al. Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J. Biol. Chem. 2004, 279:54380-54386.
57. Johnson B.S., et al. A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. Natl Acad. Sci. USA 2008, 105:6439-6444.
58. Kabashi E., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 2008, 40:572-574.
59. Kazantsev A., Walker H.A., Slepko N., Bear J.E., Preisinger E., Steffan J.S., Zhu Y.-Z., Gertler F.B., Housman D.E., Marsh J.L., Thompson L.M. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat. Genet. 2002.
60. Kazemi-Esfarjani P., Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000, 287:1837-1840.
61. Kim Y.T., et al. Expression of expanded polyglutamine protein induces behavioral changes in Drosophila (polyglutamine-induced changes in Drosophila). Cell. Mol. Neurobiol. 2004, 24:109-122.
62. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
63. Kitao Y., et al. Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum. Mol. Genet. 2007, 16:50-60.
64. Klein C., et al. Frequency of parkin mutations in late-onset Parkinson's disease. Ann. Neurol. 2003, 54:415-416. author reply 416-417.
65. Klement I.A., et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice [see comments]. Cell 1998, 95:41-53.
66. Kraemer B.C., et al. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010, 119:409-419.
67. Kretzschmar D., et al. Glial and neuronal expression of polyglutamine proteins induce behavioral changes and aggregate formation in Drosophila. Glia 2005, 49:59-72.
68. Kruger R., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
69. Kwong L.K., et al. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007, 114:63-70.
70. Le Mee G., et al. Repeat length and RNA expression level are not primary determinants in CUG expansion toxicity in Drosophila models. PLoS ONE 2008, 3:e1466.
71. Lee S.B., et al. Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem. Biophys. Res. Commun. 2007, 358:534-539.
72. Lesage S., et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J. Med. 2006, 354:422-423.
73. Lessing D., Bonini N.M. Polyglutamine genes interact to modulate the severity and progression of neurodegeneration in Drosophila. PLoS Biol. 2008, 6:e29.
74. Lessing D., Bonini N.M. Maintaining the brain: insight into human neurodegeneration from Drosophila melanogaster mutants. Nat. Rev. Genet. 2009, 10:359-370.
75. Li Z., et al. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004, 119:873-887.
76. Li W., et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl Acad. Sci. USA 2005, 102:2162-2167.
77. Li L.B., et al. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 2008, 453:1107-1111.
78. Li Y., et al. A Drosophila model for TDP-43 proteinopathy. Proc. Natl Acad. Sci. USA 2010, 107:3169-3174.
79. Lincoln S.J., et al. Parkin variants in North American Parkinson's disease: cases and controls. Mov. Disord. 2003, 18:1306-1311.
80. Liu Z., et al. A Drosophila model for LRRK2-linked parkinsonism. Proc. Natl Acad. Sci. USA 2008, 105:2693-2698.
81. Lo Bianco C., et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc. Natl Acad. Sci. USA 2004, 101:17510-17515.
82. Lu X.H., et al. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J. Neurosci. 2009, 29:1962-1976.
83. Lu Y., et al. Frontotemporal dementia and amyotrophic lateral sclerosis-associated disease protein TDP-43 promotes dendritic branching. Mol. Brain 2009, 2:30.
84. Marsh J.L., et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum. Mol. Genet. 2000, 9:13-25.
85. Menzies F.M., et al. Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress. Curr. Biol. 2005, 15:1578-1582.
86. Meulener M., et al. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr. Biol. 2005, 15:1572-1577.
87. Mishizen-Eberz A.J., et al. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 2003, 86:836-847.
88. Mishizen-Eberz A.J., et al. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 2005, 44:7818-7829.
89. Moore D.J., et al. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 2005, 14:71-84.
90. Morais V.A., et al. Parkinson's disease mutations in PINK1 result in decreased complex I activity and deficient synaptic function. EMBO Mol. Med. 2009, 1:99-111.
91. Mortiboys H., et al. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann. Neurol. 2008, 64:555-565.
92. Murata T., et al. RNA-binding protein hoip accelerates polyQ-induced neurodegeneration in Drosophila. Biosci. Biotechnol. Biochem. 2008, 72:2255-2261.
93. Murray I.V., et al. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 2003, 42:8530-8540.
94. Mutsuddi M., et al. The spinocerebellar ataxia 8 noncoding RNA causes neurodegeneration and associates with staufen in Drosophila. Curr. Biol. 2004, 14:302-308.
95. Nagai Y., et al. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum. Mol. Genet. 2003, 12:1253-1259.
96. Nelson B., et al. Isolation of gene sets affected specifically by polyglutamine expression: implication of the TOR signaling pathway in neurodegeneration. Cell Death Differ. 2005, 12:1115-1123.
97. Neumann M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
98. Ng C.H., et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J. Neurosci. 2009, 29:11257-11262.
99. Paisan-Ruiz C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
100. Pallos J., et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 2008, 17:3767-3775.
101. Pandey U.B., et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 447:859-863.
102. Park J., et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441:1157-1161.
103. Park J., et al. The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochem. Biophys. Res. Commun. 2009, 378:518-523.
104. Periquet M., et al. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J. Neurosci. 2007, 27:3338-3346.
105. Pesah Y., et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004, 131:2183-2194.
106. Pesah Y., et al. Whole-mount analysis reveals normal numbers of dopaminergic neurons following misexpression of alpha-synuclein in Drosophila. Genesis 2005, 41:154-159.
107. Petrucelli L., et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002, 36:1007-1019.
108. Petrucelli L., et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 2004, 13:703-714.
109. Phillips J.P., et al. Null mutation of copper/zinc superoxide dismutase in Drosophila confers hypersensitivity to paraquat and reduced longevity. Proc. Natl Acad. Sci. USA 1989, 86:2761-2765.
110. Pollitt S.K., et al. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron 2003, 40:685-694.
111. Polymeropoulos M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
112. Poole A.C., et al. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl Acad. Sci. USA 2008, 105:1638-1643.
113. Ratnaparkhi A., et al. A Drosophila model of ALS: human ALS-associated mutation in VAP33A suggests a dominant negative mechanism. PLoS ONE 2008, 3:e2334.
114. Ren Y., et al. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation. J. Neurosci. 2003, 23:3316-3324.
115. Rorth P. A modular misexpression screen in Drosophila detecting tissue-specific phenotypes. Proc. Natl Acad. Sci. U.S.A. 1996, 93:12418-12422.
116. Rusten T.E., et al. ESCRTing autophagic clearance of aggregating proteins. Autophagy 2007, 4.
117. Sang T.K., Jackson G.R. Drosophila models of neurodegenerative disease. NeuroRx 2005, 2:438-446.
118. Sang T.K., et al. Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. Hum. Mol. Genet. 2005, 14:357-372.
119. Sang T.K., et al. A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. J. Neurosci. 2007, 27:981-992.
120. Satterfield T.F., Pallanck L.J. Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Hum. Mol. Genet. 2006, 15:2523-2532.
121. Saudou F., et al. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
122. Scappini E., et al. Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase. Hum. Mol. Genet. 2007, 16:1862-1871.
123. Sephton C.F., et al. TDP-43 is a developmentally regulated protein essential for early embryonic development. J. Biol. Chem. 2010, 285:6826-6834.
124. Serpell L.C., et al. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl Acad. Sci. USA 2000, 97:4897-4902.
125. Shimura H., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 2000, 25:302-305.
126. Shimura H., et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001, 293:263-269.
127. Singleton A.B., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
128. Slepko N., et al. Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins. Proc. Natl Acad. Sci. USA 2006, 103:14367-14372.
129. Smith W.W., et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
130. Sreedharan J., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
131. Steffan J.S., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
132. Takeyama K., et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002, 35:855-864.
133. Tamura T., et al. Glial cell lineage expression of mutant ataxin-1 and huntingtin induces developmental and late-onset neuronal pathologies in Drosophila models. PLoS ONE 2009, 4:e4262.
134. Tan E.K., Schapira A.H. Uniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant. Eur. J. Neurol. 2008, 15:203-204.
135. Taylor J.P., et al. Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein. Genes Dev. 2003, 17:1463-1468.
136. Trinh K., et al. Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. J. Neurosci. 2008, 28:465-472.
137. Trojanowski J.Q., Lee V.M. "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann. N.Y. Acad. Sci. 2000, 924:62-67.
138. Tsuda H., et al. The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell 2008, 133:963-977.
139. Valente E.M., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
140. Van Deerlin V.M., et al. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 2008, 7:409-416.
141. Vanderklish P.W., Bahr B.A. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int. J. Exp. Pathol. 2000, 81:323-339.
142. Wang H.Y., et al. Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics 2004, 83:130-139.
143. Wang D., et al. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc. Natl Acad. Sci. USA 2006, 103:13520-13525.
144. Wang C., et al. Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities. J. Neurosci. 2007, 27:8563-8570.
145. Warrick J.M., et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998, 93:939-949.
146. Warrick J.M., et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 1999, 23:425-428.
147. Warrick J.M., et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol. Cell 2005, 18:37-48.
148. Watson M.R., et al. A Drosophila model for amyotrophic lateral sclerosis reveals motor neuron damage by human SOD1. J. Biol. Chem. 2008, 283:24972-24981.
149. Wegorzewska I., et al. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA 2009, 106:18809-18814.
150. West A.B., et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 2005, 102:16842-16847.
151. West A.B., et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 2007, 16:223-232.
152. Whitworth A.J., et al. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc. Natl Acad. Sci. USA 2005, 102:8024-8029.
153. Wils H., et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA 2010, 107:3858-3863.
154. Winton M.J., et al. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J. Biol. Chem. 2008, 283:13302-13309.
155. Wolfgang W.J., et al. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl Acad. Sci. USA 2005, 102:11563-11568.
156. Wood J.D., et al. Protein aggregation in motor neurone disorders. Neuropathol. Appl. Neurobiol. 2003, 29:529-545.
157. Wood-Kaczmar A., et al. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS ONE 2008, 3:e2455.
158. Yang Y., et al. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 2003, 37:911-924.
159. Yang Y., et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl Acad. Sci. USA 2005, 102:13670-13675.
160. Yang Y., et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl Acad. Sci. USA 2006, 103:10793-10798.
161. Yang Y., et al. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc. Natl Acad. Sci. USA 2008, 105:7070-7075.
162. Zarranz J.J., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.
163. Zhang X., et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl Acad. Sci. USA 2005, 102:892-897.
164. Zimprich A., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.